Received Nov 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RVX | ROTAVIRUS (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Stroke; partial blindness; occasional sore arm; fever; This serious case was reported by a consumer via interactive digital media and described the occurrence of stroke in a patient who received RSVPreF3 adjuvanted (RSV vaccine) for prophylaxis. On an unknown date, the patient received RSV vaccine. On an unknown date, an unknown time after receiving RSV vaccine, the patient experienced stroke (Verbatim: Stroke) (serious criteria GSK medically significant and life threatening), unilateral blindness (Verbatim: partial blindness) (serious criteria GSK medically significant and life threatening), pain in arm (Verbatim: occasional sore arm) and fever (Verbatim: fever). The outcome of the stroke, unilateral blindness, pain in arm and fever were not reported. The reporter considered the stroke and unilateral blindness to be related to RSV vaccine. It was unknown if the reporter considered the pain in arm and fever to be related to RSV vaccine. The company considered the stroke and unilateral blindness to be unrelated to RSV vaccine. It was unknown if the company considered the pain in arm and fever to be related to RSV vaccine. Additional Information: GSK Receipt Date: 30-OCT-2025 This case was reported by a patient via interactive digital media. The patient had Respiratory syncytial virus vaccine. It literally almost killed; it caused to have a massive stroke which then led to partial blindness. The reporter knows some people were against vaccines, but get all possible vaccines now. Other than an occasional sore arm, maybe a slight fever had not really had any problems with the vaccines.; Sender's Comments: A case of Cerebrovascular accident, Blindness unilateral, an unknown time after receiving RSV vaccine, in an unknown aged and unknown gender patient. Based on the available information a possible causality that the events were caused by the GSK product cannot be ascertained. Consent for further follow up has not been received.